@article {Li965, author = {Haixin Li and Hongkun Liu and Kexin Chen}, title = {Living biobank-based cancer organoids: prospects and challenges in cancer research}, volume = {19}, number = {7}, pages = {965--982}, year = {2022}, doi = {10.20892/j.issn.2095-3941.2021.0621}, publisher = {Cancer Biology \& Medicine}, abstract = {Biobanks bridge the gap between basic and translational research. Traditional cancer biobanks typically contain normal and tumor tissues, and matched blood. However, biospecimens in traditional biobanks are usually nonrenewable. In recent years, increased interest has focused on establishing living biobanks, including organoid biobanks, for the collection and storage of viable and functional tissues for long periods of time. The organoid model is based on a 3D in vitro cell culture system, is highly similar to primary tissues and organs in vivo, and can recapitulate the phenotypic and genetic characteristics of target organs. Publications on cancer organoids have recently increased, and many types of cancer organoids have been used for modeling cancer processes, as well as for drug discovery and screening. On the basis of the current research status, more exploration of cancer organoids through technical advancements is required to improve reproducibility and scalability. Moreover, given the natural characteristics of organoids, greater attention must be paid to ethical considerations. Here, we summarize recent advances in cancer organoid biobanking research, encompassing rectal, gastric, pancreatic, breast, and glioblastoma cancers. Living cancer biobanks that contain cancerous tissues and matched organoids with different genetic backgrounds, subtypes, and individualized characteristics will eventually contribute to the understanding of cancer and ultimately facilitate the development of innovative treatments.}, issn = {2095-3941}, URL = {https://www.cancerbiomed.org/content/19/7/965}, eprint = {https://www.cancerbiomed.org/content/19/7/965.full.pdf}, journal = {Cancer Biology \& Medicine} }